Department of Health Research Methods, Evidence, and Impact, Faculty of Health Sciences, McMaster University, Hamilton, Canada; Centre for Health Economics and Policy Analysis, Faculty of Health Sciences, McMaster University, Hamilton, Canada.
Department of Health Research Methods, Evidence, and Impact, Faculty of Health Sciences, McMaster University, Hamilton, Canada; Center for Pharmacoeconomics and Outcome Research, China Pharmaceutical University, Nanjing, China.
Value Health. 2024 Jun;27(6):706-712. doi: 10.1016/j.jval.2024.03.011. Epub 2024 Mar 26.
Critics of quality-adjusted life-years argue that it discriminates against older individuals. However, little empirical evidence has been produced to inform this debate. This study aimed to compare published cost-effectiveness analyses (CEAs) on patients aged ≥65 years and those aged <65 years.
We used the Tufts Cost-Effectiveness Analysis Registry to identify CEAs published in MEDLINE between 1976 and 2021. Eligible CEAs were categorized according to age (≥65 years vs <65 years). The distributions of incremental cost-effectiveness ratios (ICERs) were compared between the age groups. We used logistic regression to assess the association between age groups and the cost-effectiveness conclusion adjusted for confounding factors. We conducted sensitivity analyses to explore the impact of mixed age and age-unknown groups and all ICERs from the same CEAs. Subgroup analyses were also conducted.
A total of 4445 CEAs categorized according to age <65 years (n = 3784) and age ≥65 years (n = 661) were included in the primary analysis. The distributions of ICERs and the likelihood of concluding that the intervention was cost-effective were similar between the 2 age groups. Adjusted odds ratios ranged from 1.132 (95% CI 0.930-1.377) to 1.248 (95% CI 0.970-1.606) (odds ratio >1 indicating that CEAs for age ≥65 years were more likely to conclude the intervention was cost-effective than those for age <65 years). Sensitivity and subgroup analyses found similar results.
Our analysis found no systematic differences in published ICERs using quality-adjusted life-years between CEAs for individuals aged ≥65 years and those for individuals aged <65 years.
质量调整生命年的批评者认为,它歧视老年人。然而,几乎没有经验证据来支持这场辩论。本研究旨在比较≥65 岁患者和<65 岁患者的已发表成本效益分析(CEA)。
我们使用 Tufts 成本效益分析登记处,从 1976 年至 2021 年在 MEDLINE 中确定发表的 CEA。根据年龄(≥65 岁与<65 岁)对合格的 CEA 进行分类。比较了两组的增量成本效益比(ICER)分布。我们使用逻辑回归评估年龄组与调整混杂因素后的成本效益结论之间的关联。我们进行敏感性分析,以探讨混合年龄组和年龄未知组以及同一 CEA 的所有 ICER 的影响。还进行了亚组分析。
根据年龄<65 岁(n=3784)和年龄≥65 岁(n=661)进行分类的 4445 项 CEA 纳入主要分析。两组之间的 ICER 分布和干预措施具有成本效益的可能性结论相似。调整后的优势比范围为 1.132(95%可信区间 0.930-1.377)至 1.248(95%可信区间 0.970-1.606)(优势比>1 表示年龄≥65 岁的 CEA 更有可能得出干预措施具有成本效益的结论)。敏感性和亚组分析得出了相似的结果。
我们的分析发现,使用质量调整生命年来衡量,≥65 岁患者和<65 岁患者的已发表 ICER 之间没有系统差异。